Drug Shortage Report for TRAVASOL

Last updated on 2021-11-05 History
Report ID 147113
Drug Identification Number 00872296
Brand name TRAVASOL
Common or Proper name 10% Amino acids (Blend C) injection
Company Name BAXTER CORPORATION
Market Status MARKETED
Active Ingredient(s) LEUCINE SERINE TYROSINE PROLINE ARGININE GLYCINE L-ALANINE TRYPTOPHAN THREONINE HISTIDINE VALINE ISOLEUCINE L-LYSINE METHIONINE PHENYLALANINE
Strength(s) 730MG 500MG 40MG 680MG 1.15G 1.03G 2.07G 180MG 420MG 480MG 580MG 600MG 580MG 400MG 560MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 3000mL (JB6583)
ATC code B05BA
ATC description I.V. SOLUTIONS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2021-10-13
Actual start date 2021-10-13
Estimated end date 2021-11-04
Actual end date 2021-11-04
Shortage status Resolved
Updated date 2021-11-05
Company comments Baxter is experiencing supply constraints on Travasol 3L (Baxter Code JB6583) due to manufacturing delays. Get well is expected early November 2021. Please contact your Baxter Nutrition Sales Specialist if you have any questions or require additional information.
Health Canada comments
Tier 3 Status No
Contact Address 7125 MISSISSAUGA ROAD
MISSISSAUGA, ONTARIO
CANADA L5N 0C2
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2021-11-05 English Compare
v5 2021-11-04 French Compare
v4 2021-11-04 English Compare
v3 2021-10-14 English Compare
v2 2021-10-13 French Compare
v1 2021-10-13 English Compare

Showing 1 to 6 of 6